Androgen treatment of ERG-positive and ERG-negative cells, combined with chromatin immunoprecipitation sequencing, linked sarcosine pathway activation to the androgen receptor and ERG genes, which are key mediators in prostate cancer progression. This evidence concerns the gene ERG and prostate cancer.